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Goat weed (Ageratum conyzoides L.), or bandotan in Indonesia, is an herbaceous plant that broadly grows up in both subtropical
as well as tropical areas.'is herb contains many phytoconstituents which havemany benefits in different aspects.'e essential oil
contains phytochemicals such as phenol, phenolic ester, and coumarin, whereas many compounds can been identified in the
whole part such as terpenoid, steroid, chromene, pyrrolizidine alkaloid, and flavonoid. Empirically, this herb has been used as an
antihemorrhagic, antiseptic, antileprosy, and wound-healing agent. 'is article reviews the potency of the herb in medication
according to the chemical substances being deposited, which are collected from numerous studies, followed by its in silico
bioactivity prediction as well as its pharmaceutical dosage form formulation.
1. Introduction
'e utilization of plants as traditional medicine has been
directly changing a paradigm from the use of a synthetic
drug to a natural product (back to nature). Ageratum
conyzoides L., namely, bandotan in Indonesia, is an herb that
grows up broadly in both subtropical and tropical areas.
Ageratum was named from Ancient Greek “a geras” means
stay young and conyzoides derived from “konyz” means
plants.'is herb is genuinely from tropical America having a
goat-like smell and hence called “goat weed” in English [1].
Ageratum conyzoides L. is a family of Compositae with
Ageratum as the genus. Most of this genus is categorized as
an herb due to its height with at least 30 species. 'is herb
has stems and leaves covered by smooth white trichomes
alongside the leaves having a short petiole. Furthermore, the
leaf blade has an egg-like circular shape and 7.5 cm in length
which is sharpening up to its terminal. 'e flowers consist of
8 to 15 receptacles in either purple or white color, whereas
the fruits are black and small. 'is herb is easily found in
from rice fields, yard, jungle, roadside, and riverside having a
lot of sun exposure [2]. Figure 1 is the habitus of Ageratum
conyzoides L. photographed in Maguwoharjo, Specific Re-
gion of Yogyakarta, Indonesia.
Ageratum conyzoides L. is an annual herb with a long
history in its benefits as a traditional medicine in many
countries in the world. 'is weed has been known since the
past time for its medicinal effect in various diseases such as
common wound and the burned one, antimicrobe, arthrosis,
headache, and dyspnea. 'e further medicinal effect has
been reported such as antipneumonia, pain killer, anti-in-
flammatory agent, antiasthma, antispasmodic, haemostatic,
gastrointestinal disorder, gynaecological disorder, antilep-
rosy, and many other skin diseases [3].
In Africa, goat weed has been used traditionally to
relieve constipation and fever and applied as a wound
dressing agent as well as an antiulcer agent. In Togo, this
herb is used to treat measles and snake bite, whereas in
Nigeria, it is used for skin diseases, wound healing, diar-
rhoea, pain around the navel in children, and even used to
treat HIV/AIDS [4]. 'e leaves are consumed as vegetables
and also to prevent tetanus [5]. It is also used in the
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medication of pneumonia, antitoxin of snake venom, ty-
phoid fever, malaria fever, sore throat, and candidiasis. 'e
roots are used in the treatment of tumours, lithiasis, and
diarrhoea in a baby. Moreover, the flower is used to relieve
itching, insomnia, cough, vermifuge, tonics, and antibug
parasite [6]. Besides its benefits in medication, this weed is
also utilized in agriculture as an organic material which can
increase a soil nutrient composition. A study evaluating
this weed administration in the bokashi preparation toward
the cultivation and the nutrient composition of a tomato
plant demonstrates a significant effect in a mass of the
tomato fruits [7].
Ageratum conyzoides L. has abroad pharmacological
activities, in which one study reported that its ethanolic
extract had antiurolithiatic activity which can prevent kid-
neys from urinary stone formation [8]. 'ey also possess
pharmacological activities such as analgesics and antipyretics
[9, 10], anti-inflammation [10–12], antinociceptive [13], anti-
oxidant [11, 14], cancer cytotoxic [15], antiulcerogenic [16, 17],
antidiabetes [18–20], anticataleptic [21], antimicrobe [22, 23],
antitumor and anticancer [24, 25], hepatoprotective [26, 27],
anticonvulsant [28], radioprotective [29], anticoccidial [30],
antidote [31], antiprotozoal [32], hematopoietic [33], allelo-
pathic [34], bronchodilator dan uterine relaxant [35], anthel-
mintic [36], insecticide [37], anti-Ehrlichia [38], wound healing
[39], gastroprotective [40], and anti-HIV/AIDS [41].
Ageratum conyzoides L. contains phytochemical
substances such as terpenoid, sterol, flavonoid, chromene,
pyrrolizidine alkaloid, coumarin, pyrrolon, and lignan
[5]. Other studies also reported its essential oil phyto-
constituent includes kaempferol, rhamnoside, quercetin,
scutellarein, chromene, stigma-7-en-3-ol, sitosterol,
stigmasterol, fumaric acid, caffeic acid, saponin, pyrro-
lidine alkaloid, ageratochromene derivatives, and alkane
[6]. 'e main constituents (see Figure 2) are β-sitosterol
(1), stigmasterol (2) [42], and lycopsamine (3) in which (1)
and (2) are class of sterol, whereas (3) is pyrrolizidine
alkaloid class [43].
A recent study has reported that Ageratum conyzoides
L. leaves extract containing quercetin actively inhibited
TNF-α during the inflammation process by degrading the
collagenase of cartilage as well as the matrix metal-
loproteinase-9 (MMP-9). TNF-α is a cytokine inflammatory
agent involved in osteoarthritis, which can be worsening
inflammatory status in a blood vessel wall by inducing the
endothelial cell damage, regulating the leucocyte activity,
and releasing the cytokine as well as chemokine proin-
flammatory agent [44]. MMP-9 is a zinc-dependent pepti-
dase, a member of MMP superfamily [45]. MMP is classified
into five major groups according to their substrate specificity
which is collagenase (MMP-1, 8, and 13), gelatinase (MMP-2
and 9), stromelysin (MMP-3, 10, 11, and 19), matrilysin
(MMP-7, 12, and 18), and membrane-boundMMP (MMP-1
and 4) [46, 47].
Ageratum conyzoides L. contains phytochemicals with
various potencies in medication, particularly in the drug
discovery and development from herbal. It is also interesting
to explore the pharmacological effect as well as its phar-
maceutical formulation. 'is article reviews the active
phytoconstituents of this herb which are responsible for its
pharmacological activities followed by an in silico prediction
of the bioactivity and the pharmaceutical preparations that
have been formulated up to now.
2. Pharmacological Activities
2.1. Analgesic. 'e analgesic activity has been reported for
this herb by using alcoholic extract of a whole part of the
plant [10]. In vitro study demonstrated that Ageratum
conyzoides L. performed analgesic activity in the ovarium of
the Chinese hamster [48]. Further study by Dewan et al. also
supported that the crude ethanolic extract of its leaves
Figure 1: Habitus of Ageratum conyzoides L.
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exhibited analgesic activity in mice induced by acetic acid
[49]. During inflammation, the elevation of prostaglandin
levels affects poor pain by enhancing the capillary perme-
ability [50]. At this stage, the synthesis of prostaglandin is
inhibited through the mechanism of peripheral pain inhi-
bition leading to its analgesic effect [51]. A clinical study has
been carried out in patients with arthritis using a water
extract from the whole part of the Ageratum. 'e result
shows that 66% of the patients are relieved from their pain,
and their articulation mobility was improved by 24%
without side effects [52].
A study supported the previous study by exhibiting a
significant analgesic activity of water extract from the whole
part of Ageratum conyzoides L. using the tail flick method
[9]. 'e phytochemicals of Ageratum conyzoides L. essential
oils employing precocene I (4), precocene II (5), and 6-vinyl-
7-methoxy-2,2-dimethyl chromene (VMDC) (6) (see Fig-
ure 3) are a member of chromene compounds, responsible
for its analgesic bioactivity [53]. Furthermore, the alkaloid
and flavonoid in the oil can block the pain perception [54],
whereas other secondary metabolites such as tannin, sa-
ponin, and terpenoid also have been reported having
pharmacological activity [55].
2.2. Anti-Inflammatory Agent. 'e ethanolic extract of ag-
eratum can reduce inflammation significantly, which is
induced by carrageenan and histamine activities. 'e phy-
tochemical substances playing a role in this activity are
quercetin, kaempferol, glycoside, tannin, and other poly-
phenolic compounds [56]. 'e potential anti-inflammatory
agent from this herb due to the inflammation was induced by
raw oil which is further characterized by DNA damage in a
male Wistar mouse sperm [57]. In vitro study of this
methanolic extract also showed anti-inflammatory activity,
which supports the previous study [58]. A study related to
this standardized herbal extract by 5′-methoxynobiletin
which is a class of polymethoxyflavones (see Figure 4)
showed some benefits to overcome pain and inflammation.
'is provides a new innovation in the development of a new
drug to treat inflammation-related diseases such as rheu-
matoid arthritis [13].
One study reported that the anti-inflammatory effect of
goat weed depended on the flavonoid fraction which influ-
enced the protein expression from the inflammatory gen [11].
In particular, the flavonoid glycoside fraction of this herb
showed a very potent anti-inflammatory activity [12]. In a
mouse pleural cavity, the inflammatory response is reduced
by administrating this herb’s extract, by blocking the entry of
leucocyte and the protein exudate concentration, and also
diminishing the level of the inflammatory mediator [59].
2.3. Antimicrobial Effect. 'e antimicrobial activity in both
methanol and ether extract of Ageratum conyzoides L. has
been reported.'is herb contains antimicrobial components
which are useful against oxidase enzyme in bacteria which is
a pathogen and related to the systemic infection, leading to
deadly effect in animal and human [22]. Another study also
explores that essential oil in Ageratum conyzoides L. had a
potential antimicrobial towards Escherichia coli and Kleb-
siella pneumoniae (uropathogenic bacteria) and, therefore, is
useful in the prophylactic of urinary tract infection [60].
'e antimicrobial activity assay from both root and leaf
extracts demonstrates antibacterial and antifungal activities
against the isolate of Bacillus subtilis (Gram positive),
Escherichia coli, Klebsiella pneumoniae, Pseudomonas aer-
uginosa, Staphylococcus aureus, Salmonella typhi (Gram
negative), and fungal strain, i.e., Aspergillus niger, Candida
albicans, Penicillium notatum, and Rhizopus stolon [61]. 'e
essential oil of Ageratum conyzoides L. leaves has antibac-
terial activity in inhibiting Salmonella enteritidis [62]. 'e
leaves and stem extract of Ageratum conyzoides L. can be
used as a broad-spectrum antibacterial agent. Moreover, the
in vitro study from the methanolic extract and n-hexane
extract of Ageratum conyzoides L. showed antifungal ac-
tivities against Fusarium solani [63]. 'e leaves and stem
extracts of Ageratum conyzoides L. contain phytochemical
substances such as flavonoid, saponin, alkaloid, tannin, and
phenol, which showed antibacterial activity depends on its
concentration against the bacterial isolate [64].
2.4. Antioxidant. 'e ethanolic extract of leaves and flowers
from Ageratum conyzoides L. demonstrated antioxidant
activities against DPPH (1,1-diphenyl-2-picryl hydrazyl) to
scavenge the free radicals. 'ose antioxidant activities are
due to the presence of phytochemicals such as flavonoids
and phenol [65]. 'is claim was supported by the study of
the potent antioxidant from methanolic extract of Ageratum
conyzoides L. stems depending on the phenolic components
[15]. 'e result shows that the leaves of the ethanolic extract
have antioxidant activity which is higher than its water
extract. 'is extract has a strong natural antioxidant effect
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Figure 2: 'e molecule structure of the main constituents of Ageratum conyzoides L.
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against the free radical and also used in the treatment of
erectile dysfunction induced by oxidative stress [14].
Further study about the antioxidant activity from the
leaves ethanolic extract has also supported the previous
study [66]. On the one hand, the methanolic extract shows
much higher antioxidant activity than its essential oils [67].
On the other hand, Ageratum conyzoides L. has a positive
effect in the redox system when it is exposed to diabetic rats
induced by streptozotocin, while increasing the glycaemic
status of those rats [68].
2.5. Antimalaria. A study shows that the water extract of
Ageratum conyzoides L. has a potency to increase the an-
timalaria activity of chloroquine and artesunate in the
plasmodial induced-rats [69]. 'e phytochemical respon-
sible for the antimalarial activities are alkaloid, glycoside,
flavonoid, saponin, tannin, and resin. In this study, the
leaves extract as well as its fraction show a significant an-
timalarial activity toward parasite plasmodium as confirmed
by in vitro or in vivo model in mice [69].
2.6. Agent for Metabolic and Degenerative Diseases.
Ethanolic extract of Ageratum conyzoides L. demonstrates
antidiarrhoea and antidiabetic activities in albino rats [19].
'e water extract also showed activity as hypoglycemic in
diabetic rats induced by normoglycemic and streptozotocin
[20]. Other studies also investigated the antidiabetic activity
of the leaves water extract by exhibiting a positive effect on
hypoglycemic activities [70]. 'e extract of goat weed has a
hypoglycemic effect which is significantly comparable to
glibenclamide [71]. Another study also reported that Ag-
eratum conyzoides L. demonstrates both hypoglycemic as
well as hypolipidemic effects in rats [72].
Ageratum conyzoides L has reported having antidiarrhoea
activity through its antispasmodic activity and the solid for-
mation of the feces mass. 'e ethanolic extract has potency as
the gastroprotective agent in rats which could be mediated by
its antioxidant properties, by blocking the calcium channel
obstruction and its antiserotonergic properties [40].
3. Toxicological Activities
Hydroalcoholic extract of Ageratum conyzoides L. could be
toxic to the liver, kidneys, and blood cells after long-term
exposure as confirmed by both in vivo and in vitro assay [4].
'erefore, the use of Ageratum conyzoides L. in a longer
duration should be carefully managed.'is toxic effect could
be due to the alkaloid total especially to pyrrolizidine. 'e
hepatotoxic effect after oral administration of the leaves
ethanolic extract has been shown in Wistar albino rats upon
three regimen doses, i.e., 200, 400, and 600mg/kg of
bodyweight within 21 days. 'e experiment shows that the
total protein serum and liver alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and alkaline
phosphatase (ALP) did not significantly change; therefore, it
can be concluded that the extract is not toxic to the liver at
those respective doses [73].
A study related to the toxicological extract of the leaves
has been carried out in rats by showing LD50 extract equal to
600mg/kg bodyweight. 'e postmortem report shows an
alteration in the intestine liver and kidneys, bleeding at
subcontracted muscles alongside intestinal tracts, para-
central hepatic necrosis, and tubulin proximal convulsion.
However, in the chronic toxicity study, the extract did not
show a significant effect in the bodyweight elevation, hae-
matology, its alanine amino serum, the aspartate amino-
transferase, and its blood nitrogen urea. 'is however
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Figure 3: Molecule structure of chromene which are responsible for the analgesic activity of Ageratum conyzoides L.
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Figure 4: Molecule structure of 5′-methoxynobiletin which is a benefit for its anti-inflammatory effects of Ageratum conyzoides L.
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depends on the dose which affected the histopathological
intestine liver and kidneys [74].
4. In Silico Prediction of Molecular
Pharmacology Mechanism
'e living organism is graded in seven levels according to
their sizes from the smallest to the biggest as follows: ionic,
atomic, molecular, cellular, tissue, organ, and body [75]. In
the past, the pharmacological activity of the drug was
mainly examined using animal experiments [76]. However,
due to the ethical clearance, the use of animal in a pre-
liminary study which means at organ and body levels has
been tightly restricted [77]. 'e technology of cell culture
and tissue engineering then significantly overcomes the
ethical issue; however, at the tissue and cellular levels, there
are still a lot of pathways of pathogenesis which made the
mechanism become more complicated [78]. Later on,
modern drug discovery has been utilizing protein, signal
transduction, genes, and nucleic acid as the therapeutic
target at the molecular level. 'is leads to a more selected
target because the drug-target interaction can be elucidated
specifically [79]. 'e advanced bioinformatics alongside
information technology facilitated the study of drug-target
interaction at the molecular level using the in silico
(computational) method before applying the in vitro ex-
periment [80].
'is section will predict the interactions of seven rep-
resentative compounds of Ageratum conyzoides with seven
proteins from respected biological activities as described
before. Table 1 organizes seven compounds which could
affect the corresponding protein target and also corresponds
to the diseases of interest. 'erefore, this prediction could
inform on how Ageratum conyzoides works against patho-
logic conditions at the molecular level. 'e in silico method
being used is molecular docking as supplemented in Sup-
plementary Materials (S1). 'e seven compounds (ligands)
are precocene I, precocene II, VMDC, beta-sitosterol,
stigmasterol, polymethoxyflavone, and pyrrolizidine,
whereas the seven proteins are human tyrosinase (5m8s)
[81], Plasmodium falciparum ornithine delta-aminotrans-
ferase (3lg0) [82], Mus musculus cyclooxygenase-2 (4cox)
[83], E. coli 4-diphosphodicytidyl-2-C-methylerythritol
synthase (1i52) [84], glycoside hydrolase family 97 from
Bacteroides thetaiotaomicron (2zq0) [85], human p53 (4ibu)
[86], and human MMP-9 (1l6j) [87].
Tyrosinase is an enzyme associating with the oxidation
process due to its function in melanin or other pigment
production from tyrosine. A compound that can inhibit
tyrosinase could be related to its antioxidant properties [88].
Ornithine delta-aminotransferase has a function to produce
nonessential amino acid proline from ornithine which is
involved in the plasmodium life cycle that leads to malaria
disease [89]. Cyclooxygenase-2 catalyses the conversion of
arachidonic acid into inflammatory mediators such as
prostaglandin, prostacyclin, and leukotriene leading to in-
flammation [90]. 4-Diphosphodicytidyl-2-C-methylery-
thritol synthase is an enzyme expressed by the bacteria cell of
E. coli having a function to catalyse the formation of
isoprenoid which is one of the components in bacteria
building block [91]. Glycoside hydrolase family 97 hydro-
lyses the glycosidic bond between oligosaccharide and
polysaccharide into monosaccharide leading to blood glu-
cose upregulation associating with diabetes [92]. p53 is a
gene suppressing a tumour gene by upregulating apoptosis.
'is gene is often associated with cancer cell proliferation
[93]. MMP-9 is gelatinase having a function as introduced
before, related to inflammation, wound healing, and cancer
metastasis [94–96].
Table 2 tabulates the molecular docking results per-
forming binding energy of seven ligands identified in Ag-
eratum conyzoides in which the lower energy (more
negative) is the stronger binding with the respected protein.
In human tyrosinase (5m8s), the chromene compound class
(precocene I, precocene II, and VMDC) has better inter-
actions than other compounds, whereas the sterol com-
pound class predominates the better interactions with
ornithine delta-aminotransferase than chromene, flavonoid,
and alkaloid. In cyclooxygenase-2, either sterol of flavonoid
has a better interaction than others, whereas flavonoid is the
best ligand to interact with 4-diphosphodicytidyl-2-C-
methylerythritol synthase. In contrast, the chromene and
alkaloids are even better in interacting with glycoside hy-
drolase than sterol and flavonoid. Compared with other
proteins, all ligands have relatively poor interactions with the
p53 gene, whereas the opportunity of Ageratum conyzoides
as anMMP-9 inhibitor could be due to the presence of sterol
and flavonoid than alkaloid and chromene.
Figure 5 visualizes the binding pose of seven ligands as
the docking results in the respected proteins/gene. Although
the binding energy is within the broad range, all ligands
occupied the same pocket of human tyrosinase. In contrast,
the ligands are divided into three binding clusters in the
pocket of the human p53 gene. As happened in human p53,
the ligands have two different binding positions in the
pocket of glycoside hydrolase.
'e binding pose of all ligands is quite stable in the
MMP-9 pocket site along with their binding energies. In
contrast, the ligands are divided into two binding site po-
sitions when they are docked into the cyclooxygenase-2
pocket. Interestingly, two ligands, i.e., beta-sitosterol and
polymethoxyflavone (5-methoxynobiletin) performed two
lowest binding energies (–8.9 and –8.5 kcal/mol, respec-
tively) when they interacted with cox-2. 'is means that
both ligands bind to the cox-2 binding site stronger than
other ligands. Although both ligands have a similar low
binding energy, however, their binding positions are dif-
ferent which could lead to a different biological activity (see
Figure 6).
In microorganisms such as E. coli and P. falciparum,
the ligands are occupying the same binding pocket of 4-
diphosphodicytidyl-2-C-methylerythritol synthase and
ornithine delta-aminotransferase, respectively. Moreover,
the chance of Ageratum conyzoides to be antibacterial and
antimalarial agents is opened due to the relatively lower
binding energies as well as its stable conformations during
interaction with the corresponding proteins (see
Figure 7).
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5. Pharmaceutical Formulation
'e formulation utilizing extract from goat weed has been
carried out. Extract of goat weed could be developed into a
polyherbal formulation as the wound-healing agent through
a topical route. 'is formulation is composed of Ageratum
conyzoides, Ficus religiosa, Curcuma longa, and Tamarindus
indica. 'e result showed that the polyherbal formulation
has a good wound-healing effect in rats [97].
'e next study also developed the formulation of
emulsifiable concentrate (EC) from the aerial part extract of
Ageratum conyzoides L. using a nontoxic solvent and
emulsifying agent. 'is study was focused on the evaluation
of such formulations as an antimicrobial agent. A diverse
solvent has been used to extract the materials, including
dichloromethane, methanol, and n-hexane. 'e identified
compounds in the extract elucidated using gas chroma-
tography-mass spectroscopy (GC-MS) showing bioactiv-
ities.'e developed EC was found more active than its crude
extract against bacteria and fungus [98].
'e success of EC formulation is developed from the
aerial part making further formulation from this herb to be
designed in a pharmaceutical gel dosage form. 'is dosage
form then tested its activity against Staphylococcus epi-
dermidis and Propionibacterium acnes. In this work, Ager-
atum conyzoides was extracted using the maceration method
in ethanol 90%. 'e antibacterial activity was determined
using the disc paper diffusion method, whereas the mini-
mum inhibitory concentration (MIC) and minimum bacte-
ricidal concentration (MBC) were determined using the
microdilution method. 'e extract was formulated into the
gel basis containing various concentrations of sodium
carboxymethyl cellulose (CMC) and hydroxypropyl meth-
ylcellulose (HPMC). 'e result showed that the dosage form
performed antibacterial activity against Staphylococcus epi-
dermidis and Propionibacterium acnes with a MIC value of
2.5%. 'e best result was performed by the formula con-
taining 4% of the sodium CMC and 2.5% of the extract. 'e
antibacterial activity of the gel was able to inhibit
14.7± 2.3mm and 15.43± 1.6mm in the zone of the growth
of Staphylococcus epidermidis and Propionibacterium acnes,
respectively [99].
A study related to the gel formulation was also developed
by Taufid and Ameilia. In this study, the extract was pre-
pared by macerating Ageratum conyzoides L. using ethanol
96%. 'e gel was composed of sodium CMC as the bases
using three different extract concentrations, i.e., 2.5%, 5%,
and 7.5%, accordingly. 'e physical quality of the gel was
evaluated employing physical appearance, homogeneity, pH,
and its dispersion force. 'e gel met the requirement as a
good dosage form, in particular with its dispersion force
within 3–5 cm [100].
A current study has developed a novel formulation
which is nanoemulgel from Ageratum conyzoides L. extract
(ACE) combined with Oldenlandia corymbosa L extract
(OCE), indicated as an anti-inflammatory agent. Nano-
emulgel ACE-OCE has been developed either individually or
in combination, having a good physical characteristic and
promising effect from its activity as an anti-inflammatory
agent for osteoarthritic therapy [101]. Table 3 organizes the
type of extracts that have been formulated in pharmaceutical
dosage forms regarding their corresponding active ingre-
dient being studied previously for their molecular interac-
tion in the protein targets of interest.
6. Discussion
'e aerial part of Ageratum conyzoides has been elaborated
above, as this plant has the potential to be developed as a
modern drug. 'e identified compound has extensively
studied its pharmacological activity as a pain killer, anti-
inflammatory, antioxidant, antimalarial, antidiabetes, anti-
cancer, and antibacterial agent. 'e most-reported com-
pounds being studied, having a responsibility toward its
pharmacological activity, are classes of chromene, sterol,
flavonoid, and alkaloid.
Table 1: Seven compounds which would be predicted to interact molecularly with the respective protein target leading to their drug effect to
the corresponding diseases.
Ligands Protein target Disease target
Precocene I Cyclooxygenase-2 PainMMP-9 Rheumatoid arthritis
Precocene II Cyclooxygenase-2 PainMMP-9 Rheumatoid arthritis
VMDC Cyclooxygenase-2 PainMMP-9 Rheumatoid arthritis
Beta-sitosterol
Tyrosinase Antioxidant
Glycoside hydrolase Hyperglycemic
4-Diphosphodicytidyl-2-C-methylerythritol Antibacteria
Stigmasterol
Human p53, MMP-9 Cancer
Tyrosinase Antioxidant
Glycoside hydrolase Hyperglycemic
4-Diphosphodicytidyl-2-C-methylerythritol Antibacteria
5-Methoxynobiletin MMP-9 Rheumatoid arthritisOrnithine delta-aminotransferase Antimalaria
Lycopsamine Ornithine delta-aminotransferase Antimalaria
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Figure 6: Binding pose of seven ligands identified from Ageratum conyzoides in the pocket of (a) MMP-9 and (b) cyclooxygenase-2. 'e
protein was presented in a ribbon model, whereas the ligands were in a stick form.
Figure 7: Binding pose of seven ligands identified from Ageratum conyzoides in the pocket of (a) 4-diphosphodicytidyl-2-C-methyler-
ythritol synthase and (b) ornithine delta-aminotransferase.'e protein was presented in a ribbon model, whereas the ligands were in a stick
form.
Table 2: Docking results performing binding energy of ligands from Ageratum conyzoides interacting with seven proteins playing a role in
diverse pathologic condition.
Ligands
Binding energies (kcal/mol)
5m8s 3lg0 4cox 1i52 2zq0 4ibu 1l6j
Precocene I −7 −7.2 −7.7 −6.2 −6.4 −4.2 −5.1
Precocene II −6.8 −7 −7.6 −6 −6 −4.3 −5.3
VMDC −7.4 −8 −7.5 −6.3 −6.1 −4.6 −5.3
Beta-sitosterol 1.8 −8.3 −8.9 −6.6 −2.5 −2.7 −6.9
Stigmasterol −2.8 −8.4 −7.4 −6.8 −4 −3 −6.6
5-Methoxynobiletin −4.7 −5.9 −8.5 −7 −3.5 −1.5 −6.2
Lycopsamine −5.6 −4.5 −5.8 −5.1 −6.1 −4.3 −5.1
Figure 5: Binding pose of seven ligands identified from Ageratum conyzoides in the pocket of (a) human tyrosinase, (b) human p53, and (c)
glycoside hydrolase. 'e protein was presented in a ribbon model, whereas the ligands were in a stick form.
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'e chromene compounds studied as an analgesic drug
are corresponding with its in silico prediction in which
precocene I, precocene II, and VMDC performed relatively
good energy bindings in cox-2. Furthermore, poly-
methoxyflavone studied as anti-inflammatory agents is
exhibiting better binding energy with cox-2 than chromene
and other ligands. Flavonoids such as polymethoxyflavone
also were studied as an antibacterial against E. coli which
could be due to the 4-diphosphodicytidyl-2-C-methylery-
thritol synthase inhibition. In contrast, the interaction of
pyrrolizidine alkaloids with ornithine delta-aminotransfer-
ase seems like not related to its antimalarial property;
therefore, there should be other proteins/genes expressed by
P. falciparum abled to be targeted in claiming the antima-
larial agent. In the antidiabetic activity, the hypoglycemic
effect ofAgeratum conyzoides could be due to the presence of
chromene compounds. In the in silico prediction, precocene
I, precocene II, and VMDC show lower binding energy than
other compounds in Ageratum. 'e activity of goat weed as
an MMP-9 inhibitor could be due to the sterol compounds
since this class exhibits relatively good binding energies in
the in silico prediction. 'is activity could associate with its
pharmacological activity as an anticancer. 'e correlation
between in silico and the classical study is highlighted in
Table 4.
In the topical pharmaceutical formulation aspect, Ag-
eratum combined with other herbals has been well applied.
'e choice in the topical route could be due to some reasons.
First, this herb is most likely indicated as a wound-healing
agent either in the common wound or burned, antimicrobe,
and arthrosis, by a topical route, and the drug would be
interacting faster with the target site via local effect. Second,
the topical route is chosen according to the toxicological
effect of the liver, kidneys, and blood cells after long-term
exposure as confirmed by both in vivo and in vitro assay. Last
but not least, the unpleasant smell of goat weed could be the
reason why the nonsystemic route such as topical is pref-
erable for its pharmaceutical dosage form. 'e gel formu-
lation is suitable for its indication in burns healing process
due to its water base preparation giving cool and com-
fortable feeling during application. Moreover, the water-
based gel may easily be absorbed by the wound dissolving
like an interface between the gel and the wound excretes.
7. Conclusion
Based on the review, Ageratum conyzoides L. has a great deal
of potency and clinical effect which is beneficial. Further
efforts should be continued to decide the toxicity and ad-
verse side effect of this herbal extract in the clinical study
because there have not studied the specific toxicity as well as
its adverse side effect. To date, there has not been much
development in the formulation of this herb by using more
advanced technology which can increase the economic value
of this plant. 'erefore, this could be a good innovation in
the development of dosage form formulation utilizing Ag-
eratum conyzoides L.
Data Availability
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Table 3: Types of ageratum extract formulated in pharmaceutical dosage form, the respective active ingredients, and the protein target being
studied.
Extract
Formulation Active ingredient Protein target
Part Solvent
Root Ethanol Ointment Alkaloids Ornithine delta-aminotransferase
Aerial part Methanol Emulsifiable Precocene I Cyclooxygenase-2, MMP-9Concentrate Precocene II
Aerial part Dichloromethane Emulsifiable Precocene I Cyclooxygenase-2, MMP-9Concentrate Precocene II
Aerial part Hexane Emulsifiable concentrate Precocene I Cyclooxygenase-2, MMP-9Precocene II
Leaves Ethanol Gel Alkaloids, flavonoids Ornithine delta-aminotransferase, MMP-9
Aerial part Ethanol Nanoemulgel Alkaloids, flavonoids Ornithine delta-aminotransferase, MMP-9
Table 4: Correlation between in silico and the classical study of seven compounds identified in Ageratum in which most of compounds have
a positive correlation except for lycopsamine.
Compounds In silico methods Classical methods 'erapy
Precocene I + + Pain management, antidiabetes
Precocene II + + Pain management, antidiabetes
VMDC + + Pain management, antidiabetes
Beta-sitosterol + + Anticancer
Stigmasterol + + Anticancer
5-Methoxynobiletin + + Antibacterial agent
Lycopsamine − + Antimalaria
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